Highlights & Chart Patterns of Glenmark Pharmaceuticals Ltd.
Strong price drop. Caution keep a Tab on volume.
Short Term Resistance Line, Top Points :444.85/20-Mar-23 00:00 448.2/23-Feb-23 00:00 440.4/21-Dec-22 00:00 439.55/14-Dec-22 00:00 438.3/29-Nov-22 00:00 435.1/15-Nov-22 00:00
Long Term Support Line, Bottom Points : 371.15/30-Jan-23 00:00 368.0/26-Sep-22 00:00
Short Term Support Line, Bottom Points : 415.8/14-Mar-23 00:00 416.45/03-Mar-23 00:00
Bearish Reversal , Awesome Oscillator weaker twin peak.Awesome Oscillator Divergence Short Term Top Price Points 20-Mar-23, 23-Feb-23, & Awesome Oscillator points 23-Mar-23, 27-Feb-23, Awesome Oscillator Divergence Short Term Top Price Points 20-Mar-23, 23-Feb-23, & Awesome Oscillator points 23-Mar-23, 27-Feb-23,
Share Price History of Glenmark Pharmaceuticals Ltd.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes GBR 310, a biosimilar candidate, which is in Phase 2 clinical trial for the treatment of asthma and chronic idiopathic urticaria; and GRC 39815, a retinoid-related orphan receptor gamma t (ROR"t) inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; GRC 17536, a targeting transient receptor potential ankyrin 1 inhibitor, which is in Phase 2 clinical trial for the treatment of diabetic peripheral neuropathy; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. The company's pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, it offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Steps To Customise this view
You can now customize Equity with technical , SMA , Fin Data, chart patterns in one Page. Click here to view guide
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick
TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential
TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.